| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Girshick Birgit | Corporate Executive VP & COO | C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE STREET, WILMINGTON | /s/ Birgit Girshick | 02 Feb 2026 | 0001732091 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRL | Common Stock | Award | $0 | +9,500 | +46% | $0.000000 | 29,974 | 30 Jan 2026 | Direct | F1 |
| transaction | CRL | Common Stock | Tax liability | $647,952 | -3,061 | -10% | $211.68 | 26,913 | 30 Jan 2026 | Direct | |
| holding | CRL | Common Stock | 45,470 | 30 Jan 2026 | Revocable Trust | F2 |
| Id | Content |
|---|---|
| F1 | Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. |
| F2 | Reflects the exempt transfer pursuant to Rule 16a-13 of 45,470 shares held directly by the reporting person to a revocable trust controlled by the reporting person. |